Volume 6.39 | Oct 16

Prostate Cell News 6.39 October 16, 2015
Prostate Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PCN on Twitter
 
TOP STORY
Prostate Cells Undergo ‘Reprogramming’ to Form Tumors
Scientists have gained a key insight into how prostate tumors get their start – not by rewriting the normal DNA code, but by reprogramming the master regulator of genes in prostate cells to drive malignant growth. [Press release from Dana-Farber Cancer Institute discussing online publication in Nature Genetics]
Press Release | Abstract
Development of Simplified and Defined Cell Culture for hPSCs - Watch Now!
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-Like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages
Scientists investigated the telomere biology of cell subpopulations from benign prostatic hyperplasia patients undergoing transurethral resection of prostate. Measurement of TERC, TERT, and telomerase activity revealed that only the epithelial stem-like and progenitor fractions expressed high levels of telomerase activity and individual enzyme components. [Eur Urol] Abstract | Press Release

Optimization of TRPV6 Calcium Channel Inhibitors Using a 3D Ligand-Based Virtual Screening Method
Researchers report the discovery of the first potent and selective inhibitor of TRPV6, a calcium channel overexpressed in breast and prostate cancer, and its use to test the effect of blocking TRPV6-mediated Ca2+-influx on cell growth. [Angew Chem Int Ed Engl] Abstract

The Androgen Receptor Controls Expression of the Cancer-Associated sTn Antigen and Cell Adhesion through Induction of ST6GalNAc1 in Prostate Cancer
Scientists used RNA-Seq coupled with bioinformatic analyses of androgen-receptor (AR) binding sites and clinical prostate cancer (PCa) expression array data to identify ST6GalNAc1 as a direct and rapidly activated target gene of the AR in PCa cells. [Oncotarget] Full Article

miR-573 Inhibits Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition
Researchers found that microRNA-573 (miR-573) expression is significantly lower in metastatic tissues than matched primary prostate cancer (PCa). Its downregulation is correlated with high Gleason score and cancer-related mortality of PCa patients. [Oncotarget] Full Article

GSTP1 Loss Results in Accumulation of Oxidative DNA Base Damage and Promotes Prostate Cancer Cell Survival following Exposure to Protracted Oxidative Stress
Scientists explored the effects of restored glutathione S-transferase π (GSTP1) expression on glutathione levels, accumulation of oxidative DNA damage, and prostate cancer cell survival following oxidative stress induced by protracted, low dose rate ionizing radiation. [Prostate] Abstract

CSL Regulates AKT to Mediate Androgen Independence in Prostate Cancer Progression
A subpopulation of casodex resistant prostate cancer cells were identified with an overexpressed androgen receptor and aggressive phenotypes, characterized with high proliferation, invasion in vitro and enhanced tumorigenesis in vivo. [Prostate] Abstract

Intrauterine Exposure to Bisphenol A Promotes Different Effects in Both Neonatal and Adult Prostate of Male and Female Gerbils (Meriones unguiculatus)
Investigators describe the prostate development in both male and female neonatal gerbils in normal conditions and under exposure to bisphenol A (BPA) during intrauterine life, and also to analyze whether the effects of intrauterine exposure to BPA remain in adulthood. [Environ Toxicol] Abstract

Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples
Researchers compared pituitary adenylate cyclase-activating polypeptide (PACAP)-like immunoreactivity in different healthy and pathological human samples from urogenital organs (kidney, urinary bladder, prostate, testis) with radioimmunoassay method. [J Mol Neurosci] Abstract

CLINICAL RESEARCH

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Pre-Metastatic Niche in High-Risk Localized Prostate Cancer
A randomized, Phase II clinical trial comparing axitinib for 28 days followed by radical prostatectomy and pelvic lymph node dissection (RP/PLND) to RP/LND alone was conducted, with the primary endpoint of demonstrating downregulation of VEGFR1-positve cell clustering in benign lymph nodes. [Mol Cancer Ther] Abstract

Risk of Second Primary Cancer among Prostate Cancer Patients in Korea: A Population-Based Cohort Study
As patients with prostate cancer have a long life expectancy, there is increasing interest in predicting the risk of development of a second primary cancer (SPC), and investigators therefore estimated the overall risk of developing SPCs among Korean prostate cancer patients. [PLoS One] Full Article

ProstaCult™: Serum-Free, BPE-Free Medium for Mouse Prostate Colony Assays FREE Sample Request
 
REVIEWS
P-Cadherin and the Journey to Cancer Metastasis
The overexpression of P-cadherin is linked to significant tumor promoting effects in the breast, ovarian, prostate, endometrial, skin, gastric, pancreas and colon neoplasms. The authors review the role of P-cadherin in cancer cell invasion, as well as in loco-regional and distant metastatic dissemination. [Mol Cancer] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
SCIENCE NEWS
OncBioMune Presents Data on Novel Cancer Vaccine ProscaVax
OncBioMune Pharmaceuticals, Inc. announced that Dr. Jonathan Head presented interim data on the company’s Phase I clinical trial of the novel vaccine ProscaVax for prostate cancer. [Press release from OncBioMune Pharmaceuticals, Inc. (Marketwired L.P.) discussing research presented at CRI-CIMT-EATI-AACR – The Inaugural International Cancer Immunotherapy Conference, New York] Press Release | Presentation

From our sponsor:
Learn about mucociliary differentiation of primary bronchial epithelial cells.
Watch the video.
 
INDUSTRY NEWS
Cancer Research UK Launches £100 Million Grand Challenges to Tackle the Most Important Questions in Cancer
Cancer Research UK has launched Grand Challenges – the biggest and most ambitious cancer grants in the world – which aim to overcome the greatest barriers standing in the way of beating cancer. The £100 million investment will revolutionize how we diagnose, prevent and treat cancer by uniting teams of the best scientists around the world to come up with answers to crucial questions about how to save more lives from cancer. [Cancer Research UK] Press Release

SonaCare Medical Receives FDA Clearance for Its Sonablate® High Intensity Focused Ultrasound Prostate Ablation Device
SonaCare Medical, LLC announced that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450 in the U.S. for the ablation of prostate tissue. [SonaCare Medical, LLC] Press Release

Generex Announces Memorandum of Understanding in Respect of a Phase II Clinical Trial for the Antigen Express Prostate Cancer Vaccine
Generex Biotechnology Corporation announced that its wholly-owned immunotherapeutics subsidiary, Antigen Express, Inc., has entered into a Memorandum of Understanding with CompanDX Ltd. to conduct a Phase II clinical trial of the Antigen Express proprietary prostate cancer vaccine. [Generex Biotechnology Corporation] Press Release
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Keystone Symposium – Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies
January 24-28, 2016
Vancouver, Canada

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Division Head – Medical Oncology (Fred Hutchinson Cancer Research Center)

NEW Postdoctoral Position – Epigenetics and Cancer (Moffitt Cancer Center)

Postdoctoral Position – Cancer Research (University of Texas Health Science Center at Houston)

PhD Studentships – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Associate – Bioinformatics (Baylor College of Medicine)

Clinical Research Fellow – Prostate Cancer Biology (Cancer Research UK Manchester Institute)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellow – Prostate Cancer Research (Rutgers Cancer Institute of New Jersey)

Postdoctoral Researcher – Epigenetic Modifiers (Van Andel Research Institute)

Postdoctoral Positions – Stem Cell, Development and Cancer Biology (Columbia University Medical Center)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Prostate Cell News: Archives | Events | Contact Us